Search companies

Live

Tuesday, 17 November 2026 · 579 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

Imricor Expects Initial US Sales to Exceed Prior-Year European Revenue

IMR: $1.31 -1.50% · MC: $4.5B

Imricor Medical Systems expects revenue from its initial NorthStar sales to exceed its European business’s total revenue for 2025, following its US commercial launch. Two children’s hospitals became its first US customers, with revenue from the Dallas installation expected to be recognised in the fourth quarter. Third-quarter revenue rose more than fivefold from a year earlier, while the net loss narrowed and cash stood at US$62 million. The FDA also cleared paediatric label expansions for NorthStar and the Vision-MR Diagnostic Catheter.

Source announcements: 2026-11-13 08:53 to 2026-11-13 08:56 Sydney time
Story updated 2026-11-13 10:21 Sydney time
SourcesQ3 Result Presentation2026 Q3 Form 10-QQ3 CY2026 Quarterly Activities Report & Form 10-Q Submission
Comments